Trial Profile
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior to hematopoietic stem cell transplantation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2019
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide
- Indications Acute myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Pierre Fabre
- 04 Jan 2019 Status changed from recruiting to completed.
- 22 Jun 2011 New trial record